# Chordia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chordia-therapeutics

- Industry: Biotechnology
- Headquarters: Fujisawa-shi, Japan
- Website: www.chordiatherapeutics.com/
- Total disclosed funding: $70M
- Latest round: Series C (May 19, 2022)
- Investors on record: 10

## About

Chordia Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapeutics for oncology and rare genetic disorders, aiming to address critical unmet medical needs in global healthcare markets. Founded in 2017, Chordia Therapeutics Inc. is headquartered in Fujisawa, Japan. The company develops biopharmaceutical solutions targeting specific diseases. The founders, Daisuke Morishita and Yumi Imai, have experience in the biotechnology sector. In June 2024, Chordia Therapeutics Inc. raised JPY 1.39 billion in an IPO, selling 9.1 million shares at JPY 153 per share within the expected JPY 143-153 range, on the Tokyo Stock Exchange Growth Section. The listing values Chordia Therapeutics Inc. at JPY 10.03 billion.

Chordia Therapeutics Inc. specializes in innovative biopharmaceutical solutions aimed at addressing unmet medical needs. The company's core offerings include a range of therapeutics designed to target specific diseases, with an emphasis on improving patient outcomes in areas such as oncology and rare genetic disorders. Their flagship products have undergone extensive clinical trials, demonstrating efficacy and safety for patients, and are currently in various stages of commercialization in markets such as Japan, North America, and select regions in Europe. Chordia Therapeutics serves a diverse client base that includes healthcare institutions, specialty pharmacies, and direct consumers, thereby ensuring broad accessibility to their therapeutic solutions. The company is dedicated to advancing healthcare by providing solutions that enhance the quality of life for patients facing challenging health conditions. Chordia Therapeutics generates revenue through a structured model that incorporates both B2B partnerships and direct-to-consumer sales. The company engages with healthcare providers and institutions through licensing agreements and product distribution contracts, enhancing their reach within the pharmaceutical market. Typical transactions involve the provision of therapeutics under specific agreements that outline pricing structures based on volume and delivery schedules. Customers, primarily healthcare providers and pharmacies, are expected to purchase these products at established rates, which reflect the value of the therapeutic innovations offered. Revenue streams are further supplemented by ongoing collaborations with research institutions and participation in clinical trials, contributing to the sustainability and growth of the company's financial framework.

The company plans to use the funding from the IPO to pursue its business growth and development.

## Funding rounds

- Series C, May 19, 2022, $31M — Nippon Venture Capital, SMBC Venture Capital, SBI Investment, UTokyo Innovation Platform, Shinsei Capital Partners, Nomura SPARX Investment
- Series B, Mar 29, 2019, $28M — Nippon Venture Capital, JAFCO Group, Mitsubishi UFJ Capital, SMBC Venture Capital, Kyoto University Innovation Capital, Shinsei Capital Partners
- Series A, Nov 23, 2017, $11M — Mitsubishi UFJ Capital, SMBC Venture Capital, Takeda Pharmaceutical, Kyoto University Innovation Capital

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A, Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A, Series B, Series C
- Takeda Pharmaceutical — Series A
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Series A, Series B
- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series B, Series C
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series B
- Shinsei Capital Partners (https://capitalatlas.ai/funds/shinsei-capital-partners) — Series B, Series C
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series C
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series C
- Nomura SPARX Investment (https://capitalatlas.ai/funds/nomura-sparx-investment) — Series C